Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies

Clinical Lymphoma

Volumn 3, Issue 4, 2003, Pages 225-232

  Ribeiro, Raul C ^a   Pui, Ching Hon ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Leukemia; Non Hodgkin's lymphoma; Rasburicase; Uricozyme

Indexed keywords

ALLOPURINOL; BICARBONATE; CYCLOPHOSPHAMIDE; DOPAMINE; FUROSEMIDE; MANNITOL; RASBURICASE; URATE OXIDASE; URICOZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALKALINIZATION; ALLERGIC REACTION; ANAPHYLAXIS; BRONCHOSPASM; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEVER; FLUID THERAPY; HEMOLYSIS; HEMOLYTIC ANEMIA; HIGH RISK POPULATION; HUMAN; HYDRATION; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOXEMIA; KIDNEY FAILURE; LYMPHATIC SYSTEM TUMOR; METABOLIC DISORDER; METHEMOGLOBINEMIA; MORBIDITY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATHOGENESIS; RASH; RESPIRATORY DISTRESS; REVIEW; SEPSIS; TUMOR LYSIS SYNDROME; URTICARIA;

EID: 0037360625     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.003     Document Type: Review

References (58)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605-615.
2. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334:1238-1248.
3. Lionberger JM, Armitage JO. Advances in the management of patients with non-Hodgkin's lymphoma. Exp Rev Anticancer Ther 2001; 1:43-52.
4. Merrill D, Jackson H Jr. The renal complications of leukemia. New Engl J Med 1943; 228:271-276.
5. Rieselbach RE, Bentzel CJ, Cotlove E, et al. Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Am J Med 1964; 37:872-884.
6. Arseneau J, Canellos G, Banks P, et al. American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I: clinical factors relating to prolonged survival. Am J Med 1975; 58:314-321.
7. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68:486-491.
8. List AF, Kummet TD, Adams JD, et al. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1990; 89:388-390.
9. McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 1990; 66:246-250.
10. Conger JD. Acute uric acid nephropathy. Med Clin North Am 1990; 74:859-871.
11. Perry MC, Hoagland HC, Wagoner RD. Uric acid nephropathy. JAMA 1976; 236:961-962.
12. Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973; 289:1335-1340.
13. Cadman EC, Lunberg WB, Bertino JR. Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 1977; 62:283-290.
14. Pui CH. Optimal treatment of malignancies associated with hyperuricemia. Semin Hematol 2001;38 (suppl 10): 1-3.
15. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13:273-280.
16. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38(suppl 10):4-8.
17. Scott JT, Holloway VP, Glass HI, et al. Studies of uric acid pool size and turnover rate. Ann Rheum Dis 1969; 28:366-373.
18. Cohen MP, Foa PP. Disorders associated with purine and pyrimidine metabolism. Special topics in endocrinology and metabolism. New York, NY: Alan R. Liss, 2002:95-140.
19. Stapleton FB, Linshaw MA, Hassanein K, et al. Uric acid excretion in normal children. J Pediatr 1978; 92:911-914.
20. Wilcox WR, Khalaf A, Weinberger A, et al. Solubility of uric acid and monosodium urate. Mol Biol Eng 1972; 10:522-531.
21. Fox I, Palella T, Kelley W. Hyperuricemia: a marker for cell energy crisis. N Engl J Med 1987; 317:111-112.
22. Hebert L, Lemann JJ, Petersen J, et al. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966; 45:1886-1894.
23. Allon M, Llach F. Hyperphosphatemia, hypocalcemia, and renal failure in a patient with acute leukemia. Am J Kidney Dis 1988; 11:442-445.
24. Monballyu J, Zachee P, Verberckmoes R, et al. Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 1984; 22:47-50.
25. Kaplan BS, Hebert D, Morrell RE. Acute renal failure induced by hyperphosphatemia in acute lymphoblastic leukemia. Can Med Assoc J 1981; 124:429-431.
26. Band P, Silverberg D, Henderson J, et al. Xanthine nephropathy in a patient with lymphosarcoma, treated with allopurinol. N Engl J Med 1970; 283:354-357.
27. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109:292-298.
28. Spielman WS, Thompson CI. A proposed role for adenosine in the regulation of renal hemodynamics arid renin release. Am J Physiol 1982; 242:F423-F435.
29. Hall J, Granger J, Hester R. Interactions between adenosine and angiotensin II in controlling glomerular filtration. Am J Physiol 1985; 248(3 Pt 2):F340-F346.
30. Seidemann K, Meyer U, Jansen P, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klin Padiatr 1998; 210:279-284.
31. Stapleton F, Strother D, Roy S 3rd, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic leukemia. Pediatrics 1988; 82:863-869.
32. Wolf G, Hegewisch-Becker S, Hossfeld DK, et al. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 1999; 34:E20.
33. Leach M, Parsons RM, Reilly JT, et al. Efficacy of urate oxidase (uricozyme) in tumours lysis induced urate nephropathy. Clin Lab Haematol 1998; 20:169-172.
34. Altman KI, Smull K, Guzman-Barron ES. A new method for the preparation of uncase and the effect of uricase on the blood uric acid levels of the chicken. Arch Biochem 1949; 21:158-165.
35. London M, Hudson PB. Uricolytic activity of purified uricase in two human beings. Science 1957; 125:937-938.
36. Laboureur P, Langlois C. Urate oxidase of Aspergillus flavus. I: isolation, purification, properties. Bull Soc Chim Biol (Paris) 1968; 50:811-825.
37. Laboureur P, Langlois C. Urate oxidase of Aspergillus flavus. II: metabolism, inhibition, specificity. Bull Soc Chim Biol (Paris) 1968; 50:827-841.
38. Kissel P, Lamarche M, Royer R. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 1968; 217:72-74.
39. Masera G, Jankovic M, Zurlo MG, et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982; 100:152-155.
40. Ducros J, Saingra S, Rampal M, et al. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol 1991; 35:89-90.
41. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11:1813-1816.
42. Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia. Semin Hematol 2001; 38(suppl 10):9-12.
43. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996; 14:1252-1261.
44. Atra A, Gerrard M, Hobson R, et al. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) - results of the UKCCSG 9003 protocol. Br J Cancer 1998; 77:2281-2285.
45. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4:1732-1739.
46. Pui CH, Baruchel A, Lookwood G, et al. Recombinant urate oxidase (rasburicase) prevents uric acid accumulation during chemotherapy as evidenced by urinary allantoin excretion. Proc Am Soc Clin Oncol 2002; 21:370a (Abstract #1479).
47. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19:697-704.
48. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97:2998-3003.
49. Pui CH. Rasburicase: a potent uricolytic agent. Exp Opin Pharmacother 2002; 3:433-452.
50. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15:1505-1509.
51. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase, Elitek) for prevention and treatment of malignancy-associated hyperuricemia: updated results of a compassionate use trial. Blood 2002; 100:556a (Abstract #2186).
52. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001; 38(suppl 10): 13-21.
53. Navolanic PM, Pui CH, Larson RA, et al. Elitek™ rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome: a meeting report, Dallas, Texas, January 2002. Leukemia. In press.
54. Elion GB, Yu TF, Gutman AB, et al. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45:69-77.
55. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.
56. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones - a rare complication of allopurinol therapy. N Engl J Med 1969; 280:426-427.
57. Fox IH, Kelley WN. Management of gout. JAMA 1979; 242:361-364.
58. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40:245-249.